Modern treatment of autosomal dominant polycystic kidney disease;Nowoczesne leczenie wielotorbielowatego zwyrodnienia nerek typu dorosłych

Polski Merkuriusz Lekarski

Volumn 25, Issue 148, 2008, Pages 374-379

  Wołyniec, Wojciech ^a,b   Jankowska, Magdalena Maria ^a   Rutkowski, Bolesław ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b Department of Nephrology Transplantology and Internal Medicine ^*  (Poland)

Author keywords

Polycystic kidney disease; Polycystin; Rapamycin; Somatostatin receptor agonist; Vasopressin receptor V2 antagonist

Indexed keywords

ARTICLE; HUMAN; KIDNEY POLYCYSTIC DISEASE; MIDDLE AGED; NEPHRECTOMY; TREATMENT OUTCOME;

HUMANS; MIDDLE AGED; NEPHRECTOMY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; TREATMENT OUTCOME;

EID: 56249112335     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Augustyniak-Bartosik H., Weyde W., Krajewska M. i wsp.: Autosomal dominant polycystic kidney disease-research status and clinical manifestation. Postȩpy Hig. Med. Dośw. (online), 2004, 58, 530-537.
2. Belibi F., Wallace D.P. Yamaguchi T.Y i wsp.: The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol., 2002, 13, 2723-2729.
3. Bennett W.M.: V2 receptor antagonists in cystic kidney diseases: an exciting step towards a practical treatment. J. Am. Soc. Nephrol., 2005, 16, 838-839.
4. van Dijk M.A., Breuning M.H. Duiser R. i wsp.: No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant., 2003, 18, 2314-2320.
5. van Dijk M.A., Kamper A.M., van Veen S. i wsp.: Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant., 2001, 16, 2152-2157.
6. Ecder T., Edelstein C.L., Fick-Brosnahan G.M. i wsp.: Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am. J. Nephrol., 2001, 21, 98-103
7. Ferguson J.W., Therapondos G., Newby D.E. i wsp.: Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis. Clinical science, 2003, 105, 1-8.
8. Gattone V.H., Wang X., Harris P.C. i wsp.: Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat. Med., 2003, 9, 10), 1323-1326.
9. Gile R.D., Cowley B.D., Gattone V.H. i wsp.: Effect of lovastatin on the development of polycystic kidney disease in the HanSPRD rat. Am. J. Kidney Dis., 1995, 26, 501-507.
10. Granthan J.J.: Time to treat polycystic kidney disease like the neoplastic disorders that they are. Kidney Int., 2000, 57, 239-340.
11. Greenberg A., Verbalis J.G.: Vasopressin receptor antagonists. Kidney Int., 2006, 69, 2124-2130.
12. Hadimeri H., Johansson A.C., Haraldsson B. i wsp.: CAPD in patients with autosomal dominant polycystic kidney disease. Perit. Dial. Int., 1998, 18, 429-432.
13. Hahn ST., Park S.H., Lee J.M. i wsp.: Renal artery embolization controls intractable pain in a patient with polycystic kidney disease. Cardiovasc. Intervent. Radiol., 1999, 22, 422-424.
14. Horie S.: ADPKD: molecular characterization and quest for treatment. Clin. Exp. Nephrol., 2005, 9, 282-291.
15. Imai E., Isaka Y.: Perspectives for gene therapy in renal diseases. Internal Medicine, 2004, 43, 85-96.
16. Jasik P., Sułowicz W., Kraśniak A. i wsp.: Aktualne pogla̧dy na etiologiȩ i patogenezȩ zwyrodnienia wielotorbielowatego nerek typu dorosłych (AD-PKD). Czȩś ć I: wybrane aspekty genetyczne i mechanizmy powstawania cyst. Przegla̧d Lek., 1998, 55, 542-548.
17. Jasik P., Sułowicz W., Kraśniak A. i wsp.: Aktualne pogla̧dy na etiologiȩ i patogenezȩ zwyrodnienia wielotorbielowatego nerek typu dorosłych (AD-PKD). Czȩś ć II: inne niż genetyczne czynniki wpływaja̧ce na przebieg choroby i wybrane problemy kliniczne. Przegla̧d Lek. 1998, 55, 599-606.
18. Jayapalan S., Saboorian M.H., Edmunds J.W. i wsp.: High dietary fat intake increases renal cyst diseases progression in Han:SPRD-cy rats. J. Nutr., 2000, 130, 2356-2360.
19. Koene R.A.P.: Should polycystic kidneys ever be used for renal transplantation? Nephrol. Dial. Transpant., 2001, 16, 227-229.
20. Lee V.W., Chapman J.R.: Sirolimus: its role in nephrology. Nephrology (Carlton), 2005, 10, 606-614.
21. MacRae D.K., Nemo R., Sweeney W.E. i wsp.: A novel inhibitor of tumor necrosis factor-converting enzyme ameliorates polycystic kidney disease. Kidney Int., 2001, 60, 1240-1248.
22. Michalski A., Grzeszczak W.: The effect of hypervolemia on electrolyte level and and level of volume regulating hormones in patients with autosomal dominant polycystic kidney disease. Pol. Arch. Med. Wewn., 1996, 96, 329-343.
23. Mostov K.E.: mTOR is out of control in polycystic kidney disease. Proc. Natl. Acad. Sci. USA, 2006, 103, 5247-5248.
24. Nakamura T., Sugaya T., Kawagoe Y. i wsp.: Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease. Am. J. Med. Sci., 2005, 330, 4, 161-165.
25. Namli S., Oflaz H., Turgut F. i wsp.: Improvement of endothelial dysfunction with simvastatin in patients with autosomal dominant polycystic kidney disease. Ren. Fail., 2007, 29, 55-59.
26. Nutahara K., Higashihara E., Horie S. i wsp.: Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron. Clin. Pract., 2005, 99, 18-23.
27. Ogborn M.R.: Soy protein modification of rat polycystic kidney diseases. Am. J. Physiol., 1998, 274, 541-549.
28. Olȩdzka-Orȩziak M., Wardyn K.A.: Urosepsa. W: Zakażenia uktadu moczowego. (red. Wardyn K.A., Życińska K.). Wydawnictwo Czelej, Lublin, 2006, 325-352.
29. Pinto M.A., Juliano R.V., Tobias-Machado M. i wsp.: Hand-assisted bilateral nephrectomy in a patient with adult polycystic kidney disease. Sao Paulo Med. J./Rev. Paul. Med., 2002, 120, 6, 189-191.
30. Pirson Y., Chauveau D., Torres V.: Management of cerebral aneurysms in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol., 2002, 13, 269-276.
31. Qian Q., Harris P.C., Torres V.E.: Treatment prospects for autosomaldominant polycystic kideny disease. Kidney Int., 2001, 59, 2005-2022.
32. Resnick M., Chang A.Y., Casale P.: Laparoscopic renal denervation and nephropexy for autosomal dominant polycystic kidney disease related pain in adolescents. J. Urol., 2006, 175, 2274-2276.
33. Rizk D., Chapman A.B.: Core curriculum in nephrology. Cystic and inherited kidney diseases. Am. J. Kidney Dis., 2003, 42, 1305-1317.
34. Ruggenenti P., Remuzzi A., Ondei P. et al: Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int., 2005, 68, 206-216.
35. Schrier R.W.: Optimal care of autosomal dominant polycystic kidney disease patients. Nephrology, 2006, 11, 124-130.
36. Shan Y.S., Lee P.C., Sy E. i wsp.: Polycystic kidney patent as a cadaveric donor: is it appropriate? Nephrol. Dial. Transpant., 2001, 16, 410-411.
37. Shillingford J.M., Murcia N.S., Larson C.H. i wsp.: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl. Acad. Sci. USA, 2006, 103, 5466-5471.
38. Sutowicz W., Jasik P.: Torbielowatość nerek. W: Nefrologia, (red. Ksia̧żek A, Rutkowski B.), Wydawnictwo Czelej, Lublin, 2004, 506-521.
39. Sweeney W.E., Chen Y., Nakanishi K. i wsp.: Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kideny Int., 2000, 57, 33-40.
40. Tao Y., Kim J., Faubel S. i wsp.: Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease. Proc. Natl. Acad. Sci. USA., 2005, 102, 6954-6959.
41. Tao Y., Kim J., Schrier R.W. i wsp.: Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J. Am. Soc. Nephrol., 2005, 16, 46-51.
42. Takei R., Ubara Y., Hoshino J. i wsp.: Percutaneous transcatheter hepatic artery embolization for liver cysts in autosomal dominant polycystic kidney disease. Am. J. Kidney Dis., 2007, 49, 744-752.
43. Tarasewicz A., Dȩbska-Ślizień A., Chamienia A. i wsp.: Podwójne znaczenie rapamycyny w wybranych przypadkach przeszczepienia nerki. Doniesienie zjazdowe. V Sympozjum "Postȩpy w immunosupresji w przeszczepianiu narza̧dow unaczynionych", Kraków 7-9. 12.2006.
44. Torres V.E.: Therapies to slow polycystic kidney disease. Nephron Exp. Nephrol., 2004, 98, 1-7.
45. Torres V.E.: Treatment of polycystic liver disease: one size does not fit all. Am. J. Kidney Dis., 2007, 49, 725-728.
46. Torres V.E.: Vasopressin antagonists in polycystic kidney disease. Kidney Int., 2005, 68, 2405-2418.
47. Torres V.E., Harris P. C.: Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities. J. Intern. Med., 2007, 261, 17-31.
48. Torres V.E., Harris P.C., Pirson Y.: Autosomal dominant polycystic kidney disease. Lancet, 2007, 369, 1287-1301.
49. Ubara Y., Tagami T., Sawa N. i wsp.: Renal contraction therapy for enlarged polycystic kidney by transcatheter arterial embolization in hemodialysis patients. Am. J. Kidney Dis., 2002, 39, 571-579.
50. Unsal A., Yilmaz M., Ahbap E. i wsp.: Complications in peritoneal dialysis patients with polycystic kidney disease. Doniesienie zjazdowe. ERA EDTA. Barcelona 2007 - abstarct book.
51. Wahl P.R., Serra A.L., Hir M.L. i wsp.: Inhibition of mTOR with sirolimus slows disease progression in Han.SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol. Dial. Transplant., 2006, 21, 598-604.
52. Walz G.: Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel? Nephrol. Dial. Transplant., 2006, 21, 1752-1757.
53. Wang X., Gattone V., Harris P.C. i wsp.: Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK Rat. J. Am. Soc. Nephrol., 2005, 16, 846-851.
54. Wilson P.D.: Polycystic kidney disease. N. Engl. J. Med., 2004, 350, 151-164.
55. Wołyniec W., Jankowska E., Król E. i WSP.: Rutkowski B: Czȩstość stosowania leków moczopednych u chorych z wielotorbielowatym zwyrodnieniem nerek (streszczenie zjazdowe). Nefrol. Dial. Pol., 2007, supi. 1. IX Zjazd Polskiego Towarzystwa Nefrologicznego, 42.
56. Zaman F., Nawabi A., Abreo K.D. i wsp.: Pretransplant bilateral hand-assisted laparoscopic nephrectomy in adult patients with polycystic kidney disease. JSLS, 2005, 9, 262-265.